| ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small ... - MarketWatch (press release) |
|
|
MarketWatch (press release) This randomized, double-blind, placebo-controlled trial will evaluate the safety and tolerability of CCX168 in patients with ANCA-associated renal vasculitis while assessing the potential for reducing or eliminating the use of corticosteroids in these |